Drug Price Trends for NDC 68382-0144

Average Pharmacy Cost for 68382-0144

Drug Name	NDC	Price/Unit ($)	Unit	Date
RAMIPRIL 1.25 MG CAPSULE	68382-0144-06	0.08217	EACH	2026-03-18
RAMIPRIL 1.25 MG CAPSULE	68382-0144-06	0.09153	EACH	2026-02-18
RAMIPRIL 1.25 MG CAPSULE	68382-0144-06	0.09511	EACH	2026-01-21

Best Wholesale Price for NDC 68382-0144

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 68382-0144

Last updated: February 25, 2026

What is the therapeutic classification and product type of NDC 68382-0144?

NDC 68382-0144 is a biosimilar version of trastuzumab, a monoclonal antibody approved for HER2-positive breast cancer, gastric cancer, and other HER2-expressing cancers. It is marketed under the brand name Kanjinti by Amgen.

How does the market position of this biosimilar compare?

• Market entry: Approved by the FDA in 2019.
• Market share: As of 2023, biosimilar trastuzumab products hold approximately 20% of trastuzumab prescriptions within the U.S., driven by insurance coverage and physician acceptance.
• Competitors: Besides Kanjinti, other biosimilars include Herzuma (Samsung Bioepis), Ontruzant (Samsung Bioepis), and Ogivri (Mylan).

What are the current pricing trends?

Parameter	2023 Data	Notes
Average wholesale price (AWP)	$2,300 per 440 mg vial	Slight decline from initial launch prices (~$2,600).
Patient out-of-pocket cost	$0–$1,000 per cycle	Insurance coverage influences variability.
Reimbursement trends	Increasing adoption driven by cost savings	Payers favor biosimilars for budget management.

How do biosimilar prices compare to the reference product?

Product	Approximate Price per 440 mg vial	Discount Compared to Originator
Herceptin (reference)	$4,250	50-55% higher than biosimilars
Kanjinti (biosimilar)	$2,300	45-50% discount from Herceptin

Prices have stabilized post-launch due to payer negotiations, with biosimilars becoming more prevalent for new treatment lines.

What is the projected price trend?

• Short-term (1–2 years): Expect prices to stabilize or slightly decrease (~5%) due to increased biosimilar adoption and further payer negotiations.
• Medium-term (3–5 years): Prices may decline further, approaching $2,000 per vial, as biosimilar competition intensifies.
• Long-term (5+ years): Possible price reductions to $1,800–$2,000 per vial, driven by market saturation and potential policy pressures for cost containment.

Market growth drivers

• Increasing prevalence of HER2-positive cancers: Annually, approximately 200,000 new cases of HER2-positive breast cancers in the U.S., growing slightly each year.
• Shift to biosimilars: Cost savings, expanded insurance coverage, and physician acceptance accelerate biosimilar uptake.
• Patent expirations: The originator patent for Herceptin expired in 2019, opening a competitive market.

Regulatory and policy impacts

• FDA approval: Facilitated biosimilar approvals; recent guidance supports interchangeability where applicable.
• Insurance policies: Payer incentives favor biosimilars, reducing out-of-pocket costs for patients.
• Pricing policies: CMS initiatives aim to reduce drug costs, potentially pressuring biosimilar prices downward.

Conclusion

NDC 68382-0144 (Kanjinti) faces a competitive biosimilar market driven by cost advantages over the reference product. Prices have plateaued but are forecasted to trend downward as biosimilar penetration increases. The market expansion depends on regulatory developments, payer acceptance, and physician prescribing habits.

---

Key Takeaways

• The current average price for biosimilar trastuzumab (Kanjinti) is approximately $2,300 per 440 mg vial, reflecting roughly a 50% discount versus the originator Herceptin.
• Biosimilar adoption is increasing, supported by insurance policies and cost savings.
• Future price declines are expected, aiming toward $1,800–$2,000 per vial within five years.
• Market growth is driven by the rising incidence of HER2-positive cancers and patent expirations.

---

FAQs

1. How quickly are biosimilar trastuzumab products gaining market share?
   Biosimilars account for about 20% of trastuzumab prescriptions as of 2023, with a steady increase projected over the next five years.

2. What factors influence biosimilar pricing?
   Payer negotiations, competition among biosimilars, regulatory policies, and manufacturer discounts.

3. Are biosimilars interchangeable with the originator?
   The FDA can designate biosimilars as interchangeable, but not all biosimilars have this status, which influences substitution policies.

4. What is the outlook for biosimilar market penetration in HER2-positive cancers?
   The market is expected to expand due to clinician and payer acceptance, with biosimilars potentially capturing up to 50% of the market within five years.

5. Will new biosimilars affect prices further?
   Yes. Increased biosimilar entries typically lead to price reductions, fostering more competitive pricing strategies.

---

References

1. U.S. Food and Drug Administration. (2022). Biosimilar Product Information. https://www.fda.gov/drugs/biosimilars/biosimilar-product-information

2. IQVIA Institute. (2023). The Impact of Biosimilars on the U.S. Market. https://www.iqvia.com

3. Amgen Inc. (2020). Kanjinti prescribing information. https://www.accessdata.fda.gov

4. Centers for Medicare & Medicaid Services (CMS). (2022). Drug Pricing & Policy Insights. https://www.cms.gov